Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Recruiting
A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: University of Maryland Medical System, Baltimore, Maryland +1 locations
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
11/08/2023
Locations: University of Maryland-Greenebaum Cancer Center, Baltimore, Maryland
Conditions: Head and Neck Cancer
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Recruiting
This research is being done to collect and store biological specimens (biospecimens) from people with cancer, regardless of tumor type, who are receiving treatments known or thought to have an effect on the immune system. The goal of this discovery and exploratory study is to: Understand changes in the immune system associated with various cancer treatments, in order to better design new therapies or tests to predict how these treatments might work. Identify risk factors for those who go on to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/09/2023
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Recruiting
A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/06/2023
Locations: University of Maryland Medical System, Baltimore, Maryland
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
Recruiting
The goal of this trial is to determine whether it is possible to minimize radiation dose to parts of the brain that are important for thinking and learning in children who require radiation to treat their tumor, and if this will help reduce neurocognitive (thinking and learning) impairments in these patients. Patients with newly diagnosed brain or head and neck tumors who are having radiation therapy will have neurocognitive testing and MRI imaging (both research and for regular care) done as p... Read More
Gender:
All
Ages:
Between 1 year and 26 years
Trial Updated:
05/18/2023
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Brain Tumor, Head and Neck Cancer
ASP-1929 Photoimmunotherapy (PIT) Study in in Patients With Recurrent Head/Neck Cancer
Recruiting
A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2023
Locations: Center for Cancer Research, Bethesda, Maryland
Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck